Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 54, 2019 - Issue 2
Submit an article Journal homepage
234
Views
10
CrossRef citations to date
0
Altmetric
Original Article

Intracellular concentration and transporters in imatinib resistance of gastrointestinal stromal tumor

Qiang ZhangDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ;Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medical University, Nanjing, China; View further author information
,
Zheng LiDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ;Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medical University, Nanjing, China; View further author information
,
Kangjing XuDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ;Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medical University, Nanjing, China; View further author information
,
Yi QianResearch Division of Clinical Pharmacology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; View further author information
,
Ming ChenDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ;Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medical University, Nanjing, China; View further author information
,
Luning SunResearch Division of Clinical Pharmacology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; View further author information
,
Shanshan SongDepartment of Pathology, Xuzhou Medical University Affiliated Hospital of Lianyungang, Lianyungang, China; View further author information
,
Xiaoxu HuangDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ;Department of Gastrointestinal Surgery, The First Affiliated Yijishan Hospital of Wannan Medical College, Anhui, Wuhu, ChinaView further author information
,
Zhongyuan HeDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ;Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medical University, Nanjing, China; View further author information
,
Fengyuan LiDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ;Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medical University, Nanjing, China; View further author information
,
Diancai ZhangDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ;Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medical University, Nanjing, China; View further author information
,
Li YangDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ;Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medical University, Nanjing, China; View further author information
,
Yongqing WangResearch Division of Clinical Pharmacology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; View further author information
,
Hao XuDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ;Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medical University, Nanjing, China; Correspondence[email protected]
View further author information
&
Zekuan XuDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ;Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medical University, Nanjing, China; Correspondence[email protected]
View further author information
 show all
Pages 220-226 | Received 21 Dec 2018, Accepted 26 Jan 2019, Published online: 17 Mar 2019

References

  • Ravegnini G, Sammarini G, Nannini M, et al. Gastrointestinal stromal tumors (GIST): facing cell death between autophagy and apoptosis. Autophagy. 2017;13:452–463.
  • Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–580.
  • Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–710.
  • Nannini M, Biasco G, Astolfi A, et al. An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST). J Med Genet. 2013;50:653–661.
  • Cioffi A, Maki RG. GI stromal tumors: 15 years of lessons from a rare cancer. J Clin Oncol. 2015;33:1849–1854.
  • Li J, Ye Y, Wang J, et al. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. Chin J Cancer Res. 2017;29:281–293.
  • von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:536–563.
  • Zhang Q, Xu J, Qian Y, et al. Association of imatinib plasma concentration and single nucleotide polymorphisms with adverse drug reactions in patients with gastrointestinal stromal tumors. Mol Cancer Ther. 2018;17:2780–2787.
  • Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620–625.
  • Takahashi T, Elzawahry A, Mimaki S, et al. Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2017;56:303–313.
  • Pierotti MA, Tamborini E, Negri T, et al. Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat Rev Clin Oncol. 2011;8:161–170.
  • Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865–878.
  • Patel S. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance. Cancer Treat Rev. 2012;38:467–472.
  • Ravegnini G, Urbini M, Simeon V, et al. An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. Pharmacogenom J. 2018. [Epub ahead of print].
  • Widmer N, Rumpold H, Untergasser G, et al. Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia. 2007;21:1561–1562, 1562–1564.
  • Widmer N, Colombo S, Buclin T, et al. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood. 2003;102:1142.
  • Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol. 2004;44:158–162.
  • Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11:4182–4190.
  • Chen W, Kuang Y, Qiu HB, et al. Dual targeting of insulin receptor and KIT in imatinib-resistant gastrointestinal stromal tumors. Cancer Res. 2017;77:5107–5117.
  • Berglund E, Ubhayasekera SJ, Karlsson F, et al. Intracellular concentration of the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumor cells. Anticancer Drugs. 2014;25:415–422.
  • White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006;108:697–704.
  • Turner JG, Dawson J, Cubitt CL, et al. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014;27:62–73.
  • Ween MP, Armstrong MA, Oehler MK, et al. The role of ABC transporters in ovarian cancer progression and chemoresistance. Crit Rev Oncol Hematol. 2015;96:220–256.
  • Robey RW, Pluchino KM, Hall MD, et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18:452–464.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.